Advertisement
Advertisement
NAUT
Nautilus Biotechnolgy, Inc. Common Stock
2.32
USDSponsored
-0.06
-2.52%
Nov 10, 15:58 UTC -5
Closed
After-Market
2.29
-0.03
-1.42%
Nautilus Biotechnolgy, Inc. Common Stock (NAUT) Earnings
NAUT Earnings Reports
Positive Surprise Ratio
NAUT beat 20 of 22 last estimates.
91%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$267.75K
/-$0.13
Implied change from Q3 26 (Revenue/ EPS)
+14.42%
/+8.33%
Implied change from Q4 25 (Revenue/ EPS)
--
/+18.18%
Nautilus Biotechnolgy, Inc. Common Stock earnings per share and revenue
On Oct 27, 2026, NAUT reported earnings of -0.12 USD per share (EPS) for Q3 26, beating the estimate of -0.14 USD, resulting in a 15.97% surprise. Revenue reached 234.00 thousand, compared to an expected 210.38 thousand, with a 11.23% difference. The market reacted with a +18.44% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 4 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 267.75 thousand USD, implying an increase of 8.33% EPS, and increase of 14.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Nautilus Biotechnolgy, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Nautilus Biotechnolgy, Inc. Common Stock reported EPS of -$0.12, beating estimates by 15.97%, and revenue of $234.00K, 11.23% above expectations.
How did the market react to Nautilus Biotechnolgy, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 18.44%, changed from $2.44 before the earnings release to $2.89 the day after.
When is Nautilus Biotechnolgy, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Nautilus Biotechnolgy, Inc. Common Stock's next earnings report?
Based on 4
analysts, Nautilus Biotechnolgy, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $267.75K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.